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Molecular Mechanism for the Regulation of Human
Mitochondrial NAD(P)-Dependent Malic Enzyme
by ATP and Fumarate
m-NAD-ME in both open and closed forms, in complex
with NAD, Mn2, and various transition-state analog
inhibitors [3, 14–16]. The structures established ME as
a new class of oxidative decarboxylases and revealed
the binding modes for NAD, Mn2, and the transition-
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state analogs. The structure of each ME monomer can
be divided into four domains (Figure 1A). Domains BSummary
(residues 131–277 and 467–538) and C (278–466), to-
gether with several residues from domain A, form theThe regulation of human mitochondrial NAD(P)-depen-
active site of the enzyme. The NAD cofactor in thedent malic enzyme (m-NAD-ME) by ATP and fumarate
active site is associated with the Rossmann fold of do-may be crucial for the metabolism of glutamine for
main C. Domains A (residues 23–130) and D (539–573)energy production in rapidly proliferating tissues and
are mostly involved in dimer and tetramer formation.tumors. Here we report the crystal structure at 2.2 A˚
The tetramer of the enzyme is a dimer of dimers, withresolution of m-NAD-ME in complex with ATP, Mn2,
strong interactions at the dimer interface, but weakertartronate, and fumarate. Our structural, kinetic, and
interactions at the tetramer interface (Figure 1B). Thesemutagenesis studies reveal unexpectedly that ATP is
observations with the human enzyme are confirmedan active-site inhibitor of the enzyme, despite the pres-
from our structure of the pigeon cytosolic NADP-ence of an exo binding site. The structure also reveals
dependent malic enzyme (c-NADP-ME) in a closed form,the allosteric binding site for fumarate in the dimer
which also reveals the possible molecular mechanisminterface. Mutations in this binding site abolished the
for cofactor selectivity [17].activating effects of fumarate. Comparison to the
In the structures of human m-NAD-ME, a secondstructure in the absence of fumarate indicates a possi-
NAD binding site was observed, about 35 A˚ away fromble molecular mechanism for the allosteric function of
the active site of the enzyme (Figure 1A) [3, 16]. This
this compound.
exo binding site is located near the N-terminal end of
the parallel  sheet in domain B, and several residues
Introduction from domain D also contribute to the formation of this
site. The NAD molecule in this exosite is bound using
Malic enzyme (ME; EC 1.1.1.40) catalyzes the oxidative the ADP portion of the cofactor only, and there is specific
decarboxylation of L-malate to pyruvate and CO2, with recognition of the adenine base via hydrogen bonding
the concomitant reduction of dinucleotide cofactor to its N1 and N6 atoms. Therefore, the structural informa-
NAD or NADP [1–5]: tion appears to suggest that the natural ligand of this
exosite may actually be ATP and that this might be theNAD(P)  L-malate ⇔ NAD(P)H  pyruvate  CO2 allosteric binding site for ATP in its inhibition of the
enzyme [3]. Consistent with this hypothesis, the exositeThe enzyme also requires the presence of divalent cations
does not exist in the structure of the pigeon c-NADP-(Mg2, Mn2, or others) for the catalysis. ME activity was
ME, which is not inhibited by ATP [17].first isolated from pigeon liver and has since been found
To reveal the molecular basis for the inhibition of hu-in most living organisms [6]. The amino acid sequences
man m-NAD-ME by ATP, we have determined the crystalof malic enzymes are highly conserved, from bacteria
structure of this enzyme in complex with ATP, tartronate,to man, consistent with their important biological func-
and Mn2. The structure confirms that ATP is a ligandtions, for example, photosynthesis in plants [7]. Most
in the exosite. Somewhat to our surprise, the structuremalic enzymes are homotetramers, with the monomers
revealed that ATP is also bound in the active site of thehaving about 550 amino acids (60 kDa).
enzyme, suggesting that ATP may actually be an active-The human mitochondrial NAD(P)-dependent ME
site inhibitor, rather than an allosteric inhibitor. Our kinetic(m-NAD-ME) is believed to play an important role in the
studies showed that the inhibition by ATP is competitivemetabolism of glutamine for energy production in rapidly
with NAD, consistent with the structural information. Toproliferating tissues and tumors [8–10]. The activity of
characterize the functional role of the exosite, we carriedthis enzyme is regulated by ATP as an inhibitor and by
out structure-based mutagenesis experiments that mu-fumarate as an activator [2, 11, 12]. This regulation may
tated the three Arg residues important for binding ATPbe a crucial aspect of the control of this enzyme in
in this site. Our structural and biochemical studies con-glutamine metabolism, as ATP is the ultimate product,
firmed that the triple mutant can no longer bind ATP inand fumarate is the product from the previous step,
the exosite, but the mutant is still inhibited by ATP.
of the glutamine metabolic pathway. Previous kinetic
Therefore, our structural, kinetic, and mutagenesis stud-
studies have suggested that both ATP and fumarate act
ies demonstrate that ATP is an active-site inhibitor, not
through an allosteric mechanism [9, 12, 13]. However, an allosteric inhibitor, of human m-NAD-ME.
the molecular basis for this regulation is currently not In order to determine the binding site for the activator
known. fumarate, we have included this compound in previous
We recently reported the crystal structures of human
Key words: allosteric regulation; energy metabolism; kinetics; pro-
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Figure 1. Structure of Human m-NAD-ME in
Complex with ATP, Tartronate, Mn2, and Fu-
marate
(A) Schematic drawing of the monomer of hu-
man m-NAD-ME.  strands, cyan;  helices,
yellow; connecting loops, purple. The two
ATP molecules, tartronate (labeled T ), and
fumarate are shown as stick models, colored
in gray for carbon atoms. The Mn2 ion and
its liganding water are shown as pink and red
spheres, respectively.
(B) Schematic drawing of the tetramer of the
enzyme. The monomers are colored in cyan,
green, yellow and purple, respectively. The
fumarate molecules are in the dimer interface
(labeled F ). Produced with Ribbons [30].
crystallization experiments but, so far, have not been structure of human m-NAD-ME in a “pentary” complex
with ATP, Mn2, tartronate, and fumarate at 2.2 A˚ resolu-able to locate it in the electron density map [16]. In the
tion (Table 1) (Figure 1A). There is a tetramer of theATP complexes reported here, we were able to observe
enzyme in the crystallographic asymmetric unit, and theconclusive evidence for the binding of fumarate to hu-
structures of the four monomers in this tetramer areman m-NAD-ME. The binding pocket is located in the
highly similar to each other (Figure 1B). In addition, thedimer interface, about 30 A˚ from the active site (Figure
overall structure of the monomer in the ATP complex is1B). Therefore, our structures confirm that fumarate is
essentially the same as that in the NAD complex inan allosteric activator of m-NAD-ME. Structure-based
the closed form that we reported earlier [14], with rmsmutations in the fumarate binding site abolished the
distance of 0.3 A˚ for all equivalent C atoms. The organi-activating effect of this compound. Structural compari-
zation of the tetramer in the ATP complex has only smallsons with the open form of the enzyme, obtained in
differences (roughly 0.7 rotation and 0.2 A˚ translationthe absence of fumarate, provide a possible molecular
for each of the monomers) compared to that of the NADmechanism for the allosteric effects of this compound.
complex. Therefore, our structural analyses show that
ATP binding to m-NAD-ME does not cause any signifi-
Results cant overall changes in the structure of the monomer
or the organization of the tetramer.
Structure of the ATP Complex In the active site of the enzyme, the binding modes
To characterize in detail the interactions between malic of tartronate and the divalent cation Mn2 are similar to
those observed earlier in the NAD complex [14]. Thereenzyme and the ATP inhibitor, we determined the crystal
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Table 1. Summary of Crystallographic Information
Enzyme wild-type triple mutant
Substrate analog tartronate oxalate
Maximum resolution (A˚) 2.2 2.3
Number of observations 379,495 250,429
Rmerge (%)a 9.2 (21) 5.0 (8.7)
Resolution range used for refinement 20–2.2 20–2.3
Number of reflections 123,880 119,325
Completeness (%) (2  cutoff) 95 (82) 91 (78)
R factor (%)b 20.6 (24.4) 19.3 (20.6)
Free R factor (%) 24.2 (27.1) 23.2 (25.4)
Rms deviation in bond lengths (A˚) 0.007 0.006
Rms deviation in bond angles () 1.3 1.3








Ihi. Numbers in parentheses are for the highest resolution shell.
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are only small conformational changes for the amino with a collection of charged side chains, among which
the most important are Arg197, Arg542, and Arg556 (Fig-acid residues in the active site, the sole exception being
the side chain of Arg165. This residue interacts with the ure 2B). The -phosphate of ATP is pointed in the direc-
tion of the His154 side chain. The conformation of theseC1 carboxylate group of the inhibitor (or substrate) and
the phosphates of the NAD cofactor [3]. In the ATP residues in the ATP complex is essentially the same as
in the NAD complex, with the exception of a 50 rotationcomplex, this side chain has become more disordered,
as the conformations of this residue in the four indepen- in the side chain imidazole ring of the His154 residue
(Figure 2B). These structural observations thereforedent monomers are different from each other. This prob-
ably reflects a change in the local environment of this confirm our earlier suggestion that ATP is a natural li-
gand of this exosite [3].residue (see below). Overall, there is little change in the
active site of the enzyme in the ATP complex. To our surprise, the structure revealed that ATP is
also present in the active site of the enzyme (Figure 3A).
Moreover, the conformation of the ADP portion of ATPATP Binds in the Exosite as Well
as in the Active Site is remarkably similar to that of the NAD cofactor (Figure
3B). There does not appear to be any specific recogni-As expected from structural studies of the NAD com-
plexes, an ATP molecule is bound in the exosite (Figure tion of the adenine base, as both the N1 and N6 atoms
are exposed to the solvent. The -phosphate is situated2A), showing essentially the same interaction with the
enzyme as previously observed for the ADP portion of at the opening of the active site pocket (Figure 3C), but
this group has much weaker electron density, sug-the NAD cofactor (Figure 2B) [3]. The N6 amino group
of the adenine base makes two hydrogen bonds with gesting that it may be highly disordered (Figure 3A).
Residues in the protein that form the ATP binding sitethe main chain carbonyls of residues 192 (3.4 A˚) and
556 (2.6 A˚), and the N1 ring nitrogen makes a hydrogen generally have the same conformation as in the NAD
complex (Figure 3B). The Arg165 side chain becomesbond to the main chain amide of residue 194 (3.0 A˚). This
hydrogen-bonding pattern provides specific recognition more flexible, possibly due to the presence of the addi-
tional -phosphate. In addition, the Lys345 side chain,of the adenine base (Figure 2B). The phosphate groups
of ATP are on the surface of the structure and interact which forms one side of the adenine binding pocket
Figure 2. Binding of ATP to the Exosite
(A) Final 2Fo  Fc electron density map at 2.3 A˚ resolution for the ATP molecule in the exosite. The contour level is at 1 . Also shown is a
water molecule hydrogen bonded to the ribose hydroxyls. Produced with Setor [31].
(B) Stereo diagram showing the binding of ATP to the exosite (in cyan for carbon atoms). For comparison, the binding of the ADP portion of
NAD to the exosite (gray) is also shown. Phosphorus atoms of ATP, green; phosphorous atoms of NAD, yellow. Produced with Grasp [32].
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Figure 3. Binding of ATP to the Active Site
(A) Omit 2Fo  Fc electron density map at
2.3 A˚ resolution for the ATP molecule in the
active site. The contour level is at 1 . Pro-
duced with Setor [31].
(B) Stereo diagram showing the binding of
ATP to the active site (in cyan for carbon
atoms). For comparison, the binding of the
ADP portion of NAD to the active site (gray)
is also shown.
(C) Molecular surface of human m-NAD-ME
in the active site region, colored based on
electrostatic potential. The ATP and the
NAD molecules are shown in cyan and gray
for carbon atoms, respectively. Phosphorus
atoms of ATP, green; phosphorous atoms of
NAD, yellow. Produced with Grasp [32].
(Figure 3B), shows conformational variability among the ing to the ATP affinity resin is mediated by the exosite,
in contrast to earlier suggestions that the binding isfour monomers in the ATP complex.
mediated by the active site [9].
To confirm that ATP binding to the exosite of theMutagenesis to Disrupt ATP Binding to the Exosite
triple mutant was disrupted, we determined the crystalBased on our structural analyses, residues Arg197,
structure of the triple mutant in complex with ATP, oxa-Arg542, and Arg556 may have important roles in the
late, and Mn2 at 2.3 A˚ resolution (Table 1). The overall
binding of ATP to the exosite (Figure 2B). However, these
structure of the monomer of the mutant is similar to
residues are not conserved among malic enzymes (Fig-
that of the wild-type, with rms distance of 0.4 A˚ for all
ure 4A). Human m-NAD-ME is the only one of the cur- equivalent C atoms. As with the wild-type enzyme,
rently known malic enzymes that contains Arg residues an ATP molecule is observed in the active site of the
at all three positions, and this may be the molecular structure, having essentially the same conformation and
basis for the unique presence of a binding site in this interactions with the enzyme (data not shown). The bind-
enzyme. ing modes of Mn2 and oxalate are also the same as
To dissect the functional role of this exosite in the that observed for the wild-type enzyme.
inhibition by ATP and to verify the importance of the However, we did not observe the presence of ATP in
Arg residues for binding ATP, we created mutations that the exosite (Figure 4B), therefore confirming that the
removed the positive charges of the three Arg resi- three Arg residues are crucial for ATP binding. The three
dues—R197Q, R542V, and R556Q. The mutations were mutations introduced a significant change in the electro-
selected based on sequence comparisons between the static surface potential of the exopocket (Figures 4C
malic enzymes (Figure 4A). We have prepared and char- and 4D), which may be the principal reason for the lack
acterized the mutants that carry each of the mutations of ATP binding by the triple mutant. In addition, the
separately (the single mutants), as well as the triple mu- mutations introduced steric clashes between the ade-
tant that carries all three mutations. As expected, the nine base and the enzyme (Figures 4B and 4D).
catalytic activity of the mutants is essentially the same There is also a change in the organization of the tetra-
as that of the wild-type enzyme (see below and Table mer of the triple mutant, equivalent to rotations of about
2). It was also clear that the mutants have different bio- 1.7 and translations of about 0.2 A˚ for each of the
chemical properties. While the R197Q single mutant monomers. The observed differences are more likely
could be purified using the same protocol as that for due to the mutations themselves than to the lack of ATP
the wild-type enzyme, the other two single mutants binding to the exosite. Of the three mutations, R542V is
and the triple mutant could not, as they no longer bind located in the tetramer interface; therefore, it may have
to the ATP affinity column. This suggests that ATP bind- a direct impact on the organization of the tetramer. How-
ing to the exosite may have been disrupted by these ever, the catalytic activity of the triple mutant is essen-
tially not affected (Table 2).mutations. Moreover, the results demonstrate that bind-
Regulation of Human Malic Enzyme
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Figure 4. The Exosite Is Removed by Structure-Based Mutations
(A) Sequence alignment of residues in the exo binding site. p, residues that interact with ATP; R, mutated Arg residues.
(B) Stereo diagram showing the exopocket in the triple mutant (in yellow for carbon atoms). For comparison, the binding of ATP to the wild-
type enzyme (cyan) is also shown.
(C) Molecular surface of the exosite in the wild-type enzyme. The ATP molecule is shown as a stick model.
(D) Molecular surface of the exosite in the triple mutant. The ATP molecule in the wild-type complex is shown for reference. Note the steric
clash between ATP and the mutant enzyme and the change in the electrostatic surface features. Produced with Grasp [32].
ATP Is a Competitive Inhibitor with Respect The kinetic studies showed that the triple mutant has
roughly the same catalytic activity as the wild-type en-to NAD
Our structural studies of wild-type human m-NAD-ME zyme. More importantly, the pattern of ATP inhibition of
the triple mutant is essentially identical to that of therevealed ATP binding to both the active site and the exo-
site, thus raising the question as to which of the two sites, wild-type enzyme, also with a Ki of 0.2 mM (Table 2).
This demonstrates that the inhibition by ATP occursor maybe both of them, contributes to the inhibition by
ATP. This prompted us to characterize in detail the kinet- solely through binding at the active site. ATP binding to
the exosite does not produce any recognizable effectsics of inhibition by ATP. Our kinetic results showed that
ATP is a competitive inhibitor of wild-type m-NAD-ME on the catalysis by this enzyme. Kinetic studies with
single mutants (R197Q and R542V) produced similarwith respect to NAD (Figure 5), with a Ki of about 0.2
mM (Table 2), consistent with earlier results [9, 18]. This results to those of the triple mutant (Table 2). Therefore,
contrary to prior expectations, ATP is not an allostericsuggests that ATP binding in the active site may be
inhibitory, as it would compete with NAD for the inhibitor, but, rather, an active site inhibitor of human
m-NAD-ME.enzyme.
To study the kinetic effects of ATP binding to the Our structures show that only the ADP portion of the
ATP molecule in the active site is highly ordered in theexopocket, we next characterized the ATP inhibition of
the triple mutant. Our structural studies confirmed that complex (Figure 3A), suggesting that ADP should also
be able to inhibit the enzyme. Our kinetic experimentsthe exosite can no longer bind ATP in this mutant (Figure
4D), and ATP, therefore, can only bind in the active site. confirm that ADP is a competitive inhibitor of m-NAD-
Table 2. Kinetic Parameters for the Inhibition by ATP and ADP of m-NAD-ME
Enzyme Inhibitor Km (	M)a Vmax (
103 AU/s)b Ki (mM)
Wild-type ATP 93  10 4.1  0.2 0.20  0.02
Wild-type ADP 150  14 7.0  0.3 0.99  0.08
R197Q ATP 230  18 7.1  0.3 0.58  0.06
R542V ATP 294  41 4.1  0.4 0.79  0.15
Triple mutant ATP 295  26 2.6  0.2 0.20  0.01
a Value for NAD in the absence of the inhibitor.
b Value for same concentration of various enzymes. AU, absorbance unit.
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A4, together with residues in the A1-A2 linker, form
this binding pocket (Figure 6B). One carboxylate group
of fumarate shows bidentate ion pair interactions with
the side chain of Arg91, and the other carboxylate forms
a monodentate ion pair with Arg67. At the dimer inter-
face, residues 123–130 from the other monomer, in the
linker between domain A and domain B, cover the fumar-
ate molecule (Figure 6B), which helps to shield this bind-
ing site from the solvent (Figure 6C). This pocket is highly
hydrophilic in nature. There are more than five solvent
water molecules in the pocket, bridging the interactions
between fumarate and the protein.
Both Arg67 and Arg91 are well conserved among the
plant and animal malic enzymes (Figure 7A). To confirm
the structural observations on this binding site, we made
Figure 5. ATP Is a Competitive Inhibitor of NAD the R67S and R91T single-point mutants, based on the
Lineweaver-Burk (double-reciprocal) plots for different concentra- sequence comparisons (Figure 7A). We also generated
tions of ATP illustrate the competitive behavior of the inhibition. The the E59L mutant. This residue is ion paired with Arg67
kinetic parameters were obtained by least-squares fitting to data in the structure (Figure 6B) but is not conserved among
at all ATP concentrations simultaneously [29].
the malic enzymes (Figure 7A). Our kinetic studies
showed that the wild-type enzyme is activated by about
2-fold by the presence of 5 mM fumarate and saturating
ME with respect to NAD, with an equivalent Ki of 1 mM concentrations of the substrates, whereas neither of the
(Table 2).
three mutants is affected by the presence of fumarate
To determine the nucleotide specificity of this inhibi-
(Figure 7B). Under physiological conditions, with sub-
tion, we assayed the inhibitory effects of several other
saturating amounts of the substrates, the effects of fu-
nucleotides on human m-NAD-ME. The results showed
marate on the enzyme activity can be much greater,
that GTP has an inhibitory effect on this enzyme that is
more than 20-fold based on our preliminary measure-
comparable to that of ADP (our own unpublished data).
ments (data not shown). This clearly demonstrates the
This is consistent with our structural observations, as
biological relevance of the fumarate binding pocket ob-
there is no specific recognition of the adenine base in
served in our structures. Our data also explain why pi-
the active site. Moreover, it is unlikely that GTP can bind
geon malic enzyme is not activated by fumarate, as it
in the exosite, due to the specific recognition of adenine
contains a Ser residue at position 67 (Figure 7A). At the
by that pocket. This again confirms that the inhibition
same time, it is interesting to note that the malic enzyme
by ATP and GTP occurs through the active site. On the
from Ascaris suum is activated by fumarate [20], which
other hand, CTP and TTP have no inhibitory effects on
has Arg residues at both 67 and 91, although with a Met
this enzyme, suggesting that binding in the active site
residue at 59 (Figure 7A).
may require purine nucleotides.
With the knowledge of the fumarate binding site, we
In comparison, the nucleotides ATP, ADP, and GTP
reexamined the electron density maps of our earlier
have no inhibitory effects on the pigeon c-NADP-ME
NAD complexes, which were produced in the presence
(data not shown). This is likely due to the lack of the 2-
of 5 mM fumarate [14]. Crystals of the NAD and the ATP
phosphate group on the ribose of these nucleotides, as
complexes are actually isomorphous with each other.
the natural cofactor for this enzyme is NADP. The 2-
There was clear electron density at the two carboxylate
phosphate is recognized in part by the side chain of
positions of fumarate in the earlier electron density
Lys362 in the pigeon enzyme (Figure 3B) [17, 19]. On
maps, but the two pieces of density are not connected.
the other hand, the malic enzyme from Ascaris suum
Nonetheless, residues that form this binding site in the
uses NAD as the cofactor but is not inhibited by ATP
NAD:Mn2:oxalate quaternary complex have the same
[20]. There may be additional factors that determine the
conformation as the current ATP:Mn2:tartronate:fumar-
binding affinity for ATP in the active site.
ate pentary complex. Moreover, the positions of the
solvent molecules in this pocket in the NAD complex
Binding Site for the Activator Fumarate are also similar to those observed here in the ATP com-
To locate the binding site of the activator fumarate, we plex. Therefore, it is likely that fumarate may also be
included this compound at 5 mM concentration in our bound in the earlier NAD complexes, although it might
crystallization experiments for the NAD complexes but have been more disordered.
could not observe conclusive evidence for the binding
of this compound [14]. Unexpectedly, we observed clear
electron density for fumarate in the ATP complexes re- Discussion
ported here (Figure 6A).
Fumarate is bound at the dimer interface (Figure 1B), The regulation of human m-NAD-ME by ATP and fumar-
ate is consistent with the role of human m-NAD-ME inabout 30 A˚ away from the active site, confirming that
fumarate functions through an allosteric mechanism. It the metabolism of glutamine for energy production [8,
9] and is reminiscent of the regulation of pyruvate kinaseis docked in a pocket on the surface of domain A of one
monomer (Figure 1A). Residues from helices A3 and in the glycolysis pathway [3]. The inhibition by ATP rep-
Regulation of Human Malic Enzyme
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Figure 6. The Fumarate Binding Site
(A) Final 2Fo  Fc electron density map at 2.3 A˚ resolution for fumarate, together with a water molecule. The contour level is at 1 . Produced
with Setor [31].
(B) Stereo diagram showing the binding of fumarate (in yellow for carbon atoms) to the allosteric site (in cyan and green for the two monomers).
(C) Molecular surface of m-NAD-ME dimer near the fumarate binding site (cyan and green). The fumarate molecule is mostly shielded from
the solvent.
(D) Stereo diagram showing the lack of the fumarate binding site in the open form of the enzyme (in gray for carbon atoms) [3]. The fumarate
complex in the closed form is shown in cyan and green for the two monomers. The change in the dimer organization can be recognized by
the poor fit of the second monomer (green). Produced with Grasp [32].
resents feedback control on this metabolic pathway. inhibition by ATP occurs via the active site, in contrast
to earlier expectations that ATP is an allosteric inhibitorOur kinetic analyses showed that the Ki of ATP is around
0.2 mM, suggesting that the enzyme will be mostly inac- of the enzyme [9, 13]. Therefore, ATP inhibits human
m-NAD-ME by competing with NAD for binding to thetive under normal physiological conditions, with a mito-
chondrial ATP concentration of about 2 mM. As the active site of the enzyme.
The binding of ATP to the active site is somewhatmitochondrial concentration of ADP is generally much
lower, the inhibition of this enzyme by ADP is unlikely surprising, as the pocket is highly exposed to the solvent
(Figure 3C). This may be consistent with the relativelyto be physiologically relevant.
To determine the molecular mechanism of the inhibi- low affinity of this pocket for ATP, with Ki in the millimolar
range. In contrast, NAD is bound to this site with thetion of m-NAD-ME by ATP, we determined the crystal
structure of the enzyme in complex with the inhibitor. It nicotinamide ring completely shielded from the solvent,
and the affinity of the active site for the dinucleotiderevealed the binding of ATP to both the active site and
an exosite. To dissect the functional roles of the two cofactor is in the micromolar range [21].
Our biochemical data suggest that the R197Q singlebinding sites in the inhibition, we introduced structure-
based mutations in the exosite, and our structural analy- mutant may still be able to bind ATP in the exosite, as
it can still bind to the ATP affinity column. In contrast,sis confirmed that the exosite has been “knocked out”
in the R197Q, R542V, and R556Q triple mutant. Kinetic the R542V and R556Q single mutants and the triple mu-
tant no longer bind the ATP affinity resin. This suggestsstudies showed that this triple mutant is inhibited by
ATP at essentially the same level as the wild-type en- that R542 and R556 may have a larger contribution to
the binding of ATP in the exosite, which appears to bezyme and that the inhibition is competitive relative to
NAD. These data provide conclusive evidence that the consistent with our structural information. The R197 side
Structure
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Figure 7. Structure-Based Mutations Abol-
ish the Allosteric Effects of Fumarate
(A) Sequence alignment of residues in the fu-
marate binding site. p, residues that interact
with fumarate.
(B) Effects of fumarate on the catalytic activity
of wild-type (squares) and the R67S (circles),
R91T (stars), and E59L (triangles) mutants of
m-NAD-ME. For each enzyme, the initial ve-
locity of the reaction in the absence of fumar-
ate is set at 1. The activity of the mutants is
not affected by fumarate.
chain is further away from the - and -phosphates of binding pocket is in the dimer interface, and both Arg91
and Arg129 are located next to the 2-fold axis of theATP (Figure 2B).
The binding of ATP to the exosite has little impact dimer. It is possible that fumarate promotes the reorga-
nization of the enzyme tetramer, and this may be theon the catalysis by the enzyme. Further studies will be
needed to determine whether this binding has any other molecular mechanism for its allosteric effects on the
catalysis by human m-NAD-ME.functional or structural impacts on the enzyme. It may
be possible that binding of ATP in the exopocket helps
to stabilize human m-NAD-ME under physiological con- Biological Implications
ditions.
Fumarate is the product of the previous step of the Malic enzymes catalyze the oxidative decarboxyla-
tion of malate to produce pyruvate and CO2, togetherpathway in the metabolism of glutamine for energy pro-
duction [8]. Its activation of m-NAD-ME may help ensure with the reduction of the NAD(P) cofactor. They are
widely distributed in nature and have important biologi-that there is enough ME activity when the pathway is
functional. Our studies confirm that fumarate has an cal functions, such as photosynthesis in plants and fatty
acid biosynthesis in animals. The human mitochondrialallosteric binding pocket. Arg67 and Arg91 are two im-
portant residues in fumarate binding, and their mutation NAD(P)-dependent malic enzyme (m-NAD-ME) is be-
lieved to participate in the metabolism of glutamine forcan abolish the effects of this compound. Surprisingly,
these residues are conserved in many of the plant and the production of energy in rapidly proliferating tissues
and tumors. This enzyme is regulated by ATP as ananimal malic enzymes (Figure 7A), suggesting that there
may be additional factors that control the binding of inhibitor and by fumarate as an activator. This regulation
is consistent with the functional role of this enzyme, asfumarate to malic enzymes.
Our first structure of m-NAD-ME, in a binary complex ATP is the overall product of energy metabolism and
fumarate is from the previous step in the metabolic path-with NAD, was obtained in the absence of fumarate
[3]. The fumarate binding pocket does not exist in this way. This regulation parallels that of pyruvate kinase in
the glycolysis pathway.open form structure. The side chain of Phe68 assumes
a different rotamer and blocks the binding site, and the Our studies here showed that ATP is an active site
inhibitor of the enzyme, even though there is an exoside chain guanidinium group of Arg91 is rotated away
from the binding site (Figure 6D). A major component binding site for this molecule on the enzyme. This exo
binding site appears to be unique to this enzyme, andof the conformational differences between the open and
closed forms of the enzyme is the change in the dimer its exact biological roles (if any) remain unknown. Muta-
tions in the exosite can abolish the binding of ATP butand tetramer interface (Figure 6D) [14]. The fumarate
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structure refinement was carried out with the program CNS [24],have little impact on the catalytic activity of the enzyme.
and the atomic model was rebuilt against the 2Fo  Fc electronUnder normal physiological conditions, it is likely that
density maps with the program O [25]. After initial refinement withthis enzyme is strongly inhibited by ATP, as its Ki is the protein atoms only, the resulting electron density map clearly
about 0.2 mM. showed the binding of Mn2, ATP, and tartronate in the active site,
We have also observed the binding of fumarate to as well as the binding of ATP in the exosite. The refinement statistics
are summarized in Table 1.the enzyme. The binding site is located at the dimer
The structure of the triple mutant was determined by the combinedinterface, far from the active site of the enzyme. This
molecular replacement protocol, with the program COMO [26, 27].confirms earlier kinetic studies suggesting that fumarate
The structure of m-NAD-ME in a closed form was used as the searchis an allosteric activator. Mutations of residues in this
model [14]. Reflection data between 10 and 4 A˚ resolution were used
binding pocket can desensitize the enzyme toward fu- in the calculation. The atomic model from the molecular replacement
marate, confirming the structural observations. Under solution was subjected to rigid body refinement against reflection
data between 5 and 4 A˚ resolution with CNS [24]. Calculated phasesphysiological conditions, fumarate may be able to acti-
based on this atomic model (protein atoms only) were applied tovate the enzyme by more than 20-fold. Our structural
all the observed reflections between 20 and 2.5 A˚ resolution, andstudies suggest that fumarate may induce a change in
the phase information was improved by 4-fold noncrystallographicthe organization of the tetramer of the enzyme and that
symmetry (NCS) averaging, with the program DM [28]. The atomic
this conformational change may be the molecular mech- model was rebuilt against this electron density map, which also
anism for its allosteric activating effects. revealed the binding of ATP, Mn2, and oxalate in the active site.
There is no electron density for an ATP molecule in the exosite.
NCS restraints on the main chain atoms were used during the crys-Experimental Procedures
tallographic refinement. The refinement statistics are summarized
in Table 1.Protein Expression, Purification, and Crystallization
The protocols for the expression and purification of wild-type human
m-NAD-ME have been described previously [2, 22]. Briefly, m-NAD- Kinetic Assays
ME was cloned in the pRH281 vector, overexpressed in E. coli, and The m-NAD-ME reaction buffer contained 50 mM triethanolamine-
purified by anion exchange, ATP affinity, and gel filtration chroma- HCl (pH 7.4), 10 mM MgCl2, 10 mM L-malate, 5 mM fumarate, and
tography. The site-specific mutants of human m-NAD-ME (R197Q, 0.3 mM NAD. The reaction was started by the addition of enzyme,
R542V, R556Q, R67S, R91T, and E59L) were prepared with the Quik- and the reaction velocity was determined by following A340 (absorp-
Change kit (Stratagene) and sequenced to confirm the presence of tion of NADH) for 5 min. To minimize errors in the absorbance mea-
the mutations. As some of these mutants can no longer bind the surements, a 5 cm path-length cuvette was used in all the kinetic
ATP affinity resin, we introduced a His6 tag at the C terminus of the assays.
wild-type enzyme in the pRH281 vector. With this tag, the enzymes The inhibitory effect of ATP was assayed on the wild-type m-NAD-
were purified by Ni-NTA affinity, anion exchange, and gel filtration ME, the R197Q and R542V single mutants, and the triple mutant.
chromatography. The catalytic activity of this His-tagged wild-type His-tagged proteins were used in the assays, and the protein con-
m-NAD-ME is essentially the same as that of the untagged enzyme, centrations were determined by the Bradford method. The NAD
confirming that the introduction of the affinity tag did not affect concentration was varied between 20 and 250	M, and ATP concen-
the function of the protein. This is consistent with the structural tration was varied from 0 to 0.6 mM. To avoid the depletion of Mg2
information, as the C-terminal 11 residues of the enzyme are not by ATP, a 1:1 mixture of Mg2:ATP was used. The observed kinetic
observed in the crystal structures. data showed a fully competitive pattern, and the kinetic parameters
Crystals of both untagged wild-type and His-tagged mutant hu- were obtained by least-squares fitting against data at all ATP con-
man m-NAD-ME were obtained at 4C by the hanging-drop vapor centrations [29].
diffusion method. The protein was at 8 mg/ml concentration, in a The inhibitory effect of ADP was assayed following the same
buffer containing 30 mM Tris (pH 7.4), 70 mM KCl, 10 mM ATP, 5 protocol, and the ADP concentration was varied between 0 and 1.5
mM fumarate, 5 mM MnCl2, 2 mM DTT, and 5 mM tartronate or mM. The inhibitory effects of other nucleotides (GTP, CTP, and TTP)
oxalate. The reservoir solution contained 100 mM MES (pH 6.0), were also examined.
8%–10% (w/v) PEG 20,000, and 5% (v/v) MPD. Crystals in the shape The activating effect of fumarate was assayed using reaction buff-
of thin plates appeared within two days. The crystals were trans- ers with varying amounts of fumarate (between 0 and 5 mM). The
ferred to a cryoprotection solution containing 100 mM MES (pH 6.0), initial velocities of the reactions were determined.
35% (w/v) PEG 8000, 5% MPD (v/v), and 5 mM fumarate and flash
frozen in liquid propane for X-ray analysis. Acknowledgments
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